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ABSTRACT 
Chlordiazepoxide Increases Risky Choice 
Devin Andrew Galdieri 
Probability discounting is a measure of risky choice that is correlated with maladaptive behavior 
and psychological disorders. Benzodiazepines are a class of drug on which relatively little risky-
choice research has been conducted, particularly under conditions of chronic drug exposure. 
Chlordiazepoxide, a standard benzodiazepine, was administered to rats that had been trained to 
respond on a risky-choice task in which a choice was available between a single food pellet with 
100% certainty or three food pellets with probabilities of delivery that decreased across each 
experimental session. During baseline, responding was sensitive to the programmed 
contingencies and larger-reinforcer choice decreased as the probability of delivery decreased.  
Acute administration of  chlordiazepoxide dose-dependently increased risky choice. Tolerance to 
chlordiazepoxide’s effects on larger-reinforcer-choice was observed after chronic drug exposure.  
The results of the present study indicate that acute chlordiazepoxide can increase risky choice in 
a probability-discounting task and that tolerance to this effect develops after chronic exposure to 
the drug. Limitations of the probability-discounting task and its relation to the hypothetical 
construct “risky choice” are discussed, as are suggestions for additional pharmacological targets  
and procedural variations for future studies on benzodiazepines, the GABA system, and risky 
choice.  
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Chlordiazepoxide Increases Risky Choice 
Maladaptive decision-making, a component of many psychiatric disorders and 
problematic behavior in general, can be divided into several categories. Risky choice is a 
category of maladaptive decision-making that can be conceptualized as preference for a larger, 
riskier reward over a smaller, certain reward. Risky choice can be measured using probability-
discounting procedures, which are supported by a broad literature base and can provide multiple 
measures that describe how risky choice changes as a function of environmental influences. One 
such environmental influence is pharmacological manipulation.  
Many drugs have been shown to exert effects on risky choice in human and non-human 
animals as measured by probability-discounting procedures. Benzodiazepines are a class of drugs 
that have been shown to increase some forms of risky choice in humans and non-human animals, 
but little is known about how benzodiazepines affect probability discounting in humans or non-
human animals. Benzodiazepines produce numerous effects on decision-making when 
administered acutely, and long-term use is associated with a similar but distinct set of effects. 
The present study was designed to examine effects of acute and chronic administration of a 
typical “gold-standard” benzodiazepine, chlordiazepoxide, in a well-established laboratory 
model of risky choice (i.e., a probability-discounting procedure).   
Risky Choice 
Maladaptive decision-making is a key feature of numerous psychiatric disorders, 
including attention-deficit/hyperactivity disorder (ADHD), gambling disorder, substance-use 
disorders, mood disorders, and primary psychotic disorders (Berry et al., 2019; Drechsler et al., 
2010; Hart, Brown et al., 2019; Hayashi et al., 2018; Kyonka & Schutte, 2018; Moreira et al., 
2019; Shurman et al., 2005). Maladaptive decision-making is also associated with risky sexual 
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practices, increased drug use, texting while driving, and other high-risk behavior (Chuang et al., 
2017; Dir et al., 2014; Hayashi et al., 2016). Contemporary accounts of maladaptive decision-
making often discuss separate forms of maladaptive decision-making. Excessive devaluation of 
delayed rewards (delay discounting) or suboptimal valuation of uncertain outcomes (probability 
discounting) are two commonly discussed forms of maladaptive decision-making. When 
maladaptive decision-making occurs in relation to uncertain outcomes, it is referred to as risky 
choice.  
Risky choice can be conceptualized as preference for a larger reward that is associated 
with some probability of an adverse outcome instead of a smaller reward with no probability of 
an adverse outcome. An adverse outcome may come in the form of a smaller reward, a lack of 
reward altogether, a time-out from earning rewards, and/or the addition of an aversive stimulus. 
For example, choosing to speed on the freeway in order to get to a destination quickly instead of 
driving the speed limit and arriving later could be a risky choice. There is increased probability 
of a receiving a speeding ticket when speeding (and subsequently arriving late), but also a greater 
and more likely potential reward (e.g., less time spent driving, arriving sooner).  
Often, it is advantageous to discount the value of an outcome when it is relatively 
unlikely. For example, many people take the risk of driving on the freeway every day to get to 
work because the risk of being involved in an automobile accident is relatively low, and the 
rewards associated with going to work are relatively high. However, most people choose not to 
speed on the freeway while heading to work. In this scenario, the potential to arrive at work a 
few minutes early does not outweigh the potential consequences of a citation and/or collision.  
In either case, risky choice can be related to risk aversion (some individuals may be less 
sensitive to risks) and/or reward sensitivity (some individuals may be more sensitive to rewards). 
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Consider, for example, an individual with a gambling problem who continues to spend money 
even though it is extremely unlikely that such behavior will result in a net gain. Continued 
gambling could be due to an insensitivity to loss, or to an oversensitivity to reward. On the other 
hand, the individual could simply be ineffective at determining the relative value of probabilistic 
outcomes (i.e., the economic utility of continued gambling), regardless of their sensitivity to 
winning or losing. In an effort to study this phenomenon objectively, researchers have developed 
several pre-clinical models to assess risky choice. 
Risky choice can be assessed experimentally with several procedures. Pre-clinical models 
include rat gambling tasks, the Balloon Analog Risk Task (BART), and probability-discounting 
procedures (e.g., Cardinal & Howe, 2005; Hastjarjo et al., 1990; Jentsch et al., 2010; Winstanley 
& Floresco, 2016; Zeeb et al., 2009). Rat gambling tasks typically involve a choice between 
responses that produce varying amounts of reward but are also associated with differing 
probabilities of non-reward in the form of time-out from earning rewards or no reward delivery. 
Similarly, the BART involves a choice between two responses. However, in the BART, one 
response increases the amount of reward available but also increases the likelihood that all of the 
accrued rewards will be erased (the BART takes its name from a hypothetical task in which an 
individual attempts to pump up a balloon as much as possible without popping it). The other 
response option in the BART allows for a “cash out” where the previously accrued reward 
amount is delivered. In essence, the BART involves the choice between a smaller reward with 
less risk and a larger reward with an increasing risk of loss.  
Probability-discounting procedures involve a choice between two responses as well. 
Response options include a response that produces a smaller reward every time, and a response 
that produces a larger reward with some probability of non-delivery. The probability of the larger 
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reward being delivered is manipulated (typically reduced) across trials, and the relative value of 
the larger reward is said to be discounted as a function of the probability of its non-delivery.  
Probability-discounting procedures have several advantages over other measures of risky 
choice. First, there is a robust literature base in which probability-discounting procedures have 
been used to characterize group differences in risk-taking clinical subpopulations and healthy 
controls (e.g., Drechsler et al., 2010; Kyonka & Schutte, 2018; Levy et al., 2019; Hart et al., 
2019). This literature also includes experimental data regarding various environmental and 
pharmacological manipulations that alter probability discounting (e.g., Lane et al., 2008; Lane et 
al., 2005; St. Onge, et al., 2010; St. Onge & Floresco, 2009).  Second, probability-discounting 
procedures with non-human animals typically require minimal pre-training and produce long-
lasting stability in responding, which allows for risky choice to be analyzed over time (Galdieri, 
2018; Ozga & Anderson, 2018). Third, probability-discounting procedures share some features 
with the similar yet distinct phenomenon of delay discounting. Identifying similarities and 
differences in these distinct but related forms of maladaptive decision-making is a separate, 
ongoing area of research (for a review of similarities and differences, see Green & Myerson, 
2014). Finally, probability-discounting procedures produce several useful measures that allow 
multiple levels of analysis of choice.  
There are at least five measures that can be obtained with probability-discounting 
procedures. Percent larger-reinforcer choice is the proportion of responses made for the larger, 
risky reward overall and at a given probability of delivery. Plotting percent larger-reinforcer 
choice as a function of decreasing probability of delivery yields a hyperboloid curve. Such a 
curve can be analyzed qualitatively via visual inspection and quantitatively by calculating the 
area under the curve (AUC). Indifference points (IPs) are calculated by interpolating the 
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probability value at which responses for the larger, risky reward and the smaller, certain reward 
are equally likely. Increased percent larger-reinforcer choice (specifically at low probabilities of 
delivery), increased IPs, and increased AUC are all indicative of increased risky choice.  
Trial-by-trial measures of responding can also be obtained by analyzing how responding 
changes following a non-reinforced response for the larger reinforcer (lose-shift ratio; LSR) and 
how responding persists following a reinforced response for the larger reinforcer (win-stay ratio; 
WSR). LSRs and WSRs are important because they reflect how responding is affected by recent 
extinction (lose-shift) and recent reinforcement (win-stay), and are differentially affected by 
environmental factors (Bari et al., 2010; Forder & Dyson, 2016; Reed, 2018; Thapa & Gruber, 
2018; Stopper & Floresco, 2011; Tom et al., 2007). 
Pharmacological Manipulation of Risky Choice  
One factor that affects risky choice in general is pharmacological manipulation. Drugs 
that have been shown to increase risky choice in probability-discounting experiments include 
dopaminergic drugs such as d-amphetamine and flupenthixol (e.g., St. Onge et al., 2010; St. 
Onge & Floresco, 2009). Noradrenergic drugs, such as dexmedetomidine and clonidine have 
been shown to reduce risky choice, while noradrenaline antagonists such as atomoxetine and 
reboxetine have produced mixed results, with some studies reporting increases, and others 
reporting no effect (Cui et al., 2018; Montes et al., 2015; Ozga & Anderson, 2018). Several 
studies have found no effect of serotonergic manipulations on risky choice (Anderson, et al., 
2003; Blaes et al., 2018; Mobini et al., 2000; Yang et al., 2016).  
There is some evidence that gamma-aminobutyric acid (GABA) receptors, which are 
activated by ethanol and other drugs, play a role in risky choice. Results of some studies have 
shown that acute and chronic ethanol exposure can increase risky choice in probability-
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discounting and other procedures (Bidwell et al., 2013; Schindler et al., 2014; Wallin-Miller et 
al., 2017). However, little is known about how other pharmacological manipulations of the 
GABA system affect risky choice. 
Benzodiazepines and the GABA System 
Benzodiazepines are a class of drugs that activate the GABA system. Benzodiazepines are 
prescribed for short-term treatment of conditions such as anxiety, seizures, and alcohol 
withdrawal (Kaiser Permanente, 2019). In 2017, more than one-in-eight adults reported using 
benzodiazepines at least once, with misuse accounting for approximately 17% of all use (O’Neal, 
2018). Between 2004 and 2010, emergency-department visits for benzodiazepine misuse 
increased 139% (O’Neal). Admissions to benzodiazepine-abuse treatment programs nearly 
tripled between 1998 and 2008, although admissions to drug-abuse treatment programs overall 
increased by only 11% (Schmitz, 2016).  Benzodiazepine overdose can include respiratory 
depression, muscle and brain damage, and on rare occasions death (Gross, 1992). However, fatal 
overdoses are most common when benzodiazepines are combined with other substances such as 
alcohol or opioids (NIDA, 2018). In fact, over 30% of opioid overdoses also involved 
benzodiazepines and 23% of fatal opioid overdoses involved benzodiazepines. Nevertheless, the 
rate of benzodiazepines co-prescribed with opioids increased from nine to seventeen percent 
between 2001 and 2013 (NIDA). Aside from the risk of overdose, benzodiazepine use is 
associated with various forms of risky behavior. 
Benzodiazepine use has been associated with robbery and weapons-related crimes, 
increased likelihood of criminal behavior and memory loss in forensic psychiatric patients, 
increased antisocial behavior in violent criminals, and increased likelihood of poly-drug use 
(Daderman, 2005; Daderman & Edman, 2001; Daderman et al., 2002). Benzodiazepine use has 
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also been associated with increased risk of automobile accidents, unintentional drowning, and 
increased sexual disinhibition (Leung, 2011; Orriols et al., 2011; Pajunen et al., 2017; Simoes et 
al., 2009, Van der Sluiszen et al., 2017). Because benzodiazepines act primarily on GABA 
receptors, it is likely that these risk-increasing effects are mediated at least in part by the GABA 
system.  
The GABA system has been implicated in maladaptive decision-making in human and 
non-human animals. Individuals with gambling disorders are more likely to have impaired 
GABA transmission and individuals with higher levels of cerebrospinal-fluid GABA are more 
impulsive than controls (Mick et al., 2017; Nordin & Sjodin, 2007). In non-human animals, 
GABA dysregulation is associated with increased impulsivity and risk taking, and GABA 
agonists have been shown to produce impulsive responding in rats in a reaction-time task and 
increase choice for a larger reward that is associated with some probability of foot shock (Jupp et 
al., 2013; Mitchell et al., 2011; Murphy et al., 2012; Paine et al., 2011). There is also some 
evidence to suggest that individual differences in risk-taking may be related to differential 
genetic expression of GABA receptors in certain brain regions (Ucha et al., 2019). GABA 
agonists such as diazepam, alprazolam, and flunitrazepam have also been shown to affect risky 
choice in humans. 
Benzodiazepines and Risky Choice  
Several benzodiazepines have been studied for their effects on risky choice with humans. 
In one study, human subjects were given a range of doses of diazepam and tested on a battery of 
assessments, including a risky decision-making task. Subjects were instructed to choose between 
options with varying reward sizes and varying probabilities of delivery. Diazepam increased 
risky choice at 20 mg which was the highest dose administered (Deakin et al., 2004).  
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Alprazolam and flunitrazepam have also been shown to increase risky choice in risky 
decision-making tasks with humans (Lane et al., 2005; 2008). Lane and colleagues (2005) found 
that alprazolam administration dose-dependently increased risky choice in a computerized risk-
taking task. The computerized task required subjects to choose between a risky and a non-risky 
choice by making 25 responses on a computer-screen button. The non-risky choice produced 
$0.01 and the risky choice produced either a gain or loss of $0.25 - $1.00 with equal probability. 
Lane and colleagues also administered flunitrazepam to human subjects in a separate 
(2008) study using the same computerized task and found that flunitrazepam also dose-
dependently increased risky choice. Notably, these studies employed procedures that deviate 
considerably from what may be considered “standard” pre-clinical models of risky choice, 
making comparisons of risky choice across species and experimental settings difficult. Indeed, 
little is known about how the performance of humans or non-human animals on probability-
discounting tasks is affected by benzodiazepines.  
Benzodiazepines and Tolerance 
Benzodiazepines are indicated for short-term (two to four weeks) relief of anxiety-related 
symptoms, but are may also be prescribed for much longer periods of time (Kaiser Permanente, 
2019). Recreational users and individuals who abuse benzodiazepines may also use them for 
longer periods, with many individuals developing tolerance and dependence. However, little is 
known about how repeated, chronic use affects decision-making. Similarly, little is known about 
repeated exposure to benzodiazepines and the possible development of tolerance to their effects 
on risky choice. 
In general, tolerance to the various effects of benzodiazepines develops at different rates 
and occurs due to changes in the quantity and function of GABA receptors rather than changes in 
CHLORDIAZEPOXIDE INCREASES RISKY CHOICE 9 
drug metabolism (Ferreri et al., 2015; Hutchinson et al., 1996) Some studies have shown that in 
humans, tolerance to sedative effects develops in as little as 3 – 14 days (Johnson & Streltzer, 
2013; Potts & Krishnan, 1992). In addition to tolerance, long-term use of benzodiazepines is 
associated with cognitive impairments, increased risk for automobile accidents, increased risk of 
hip fracture in elderly populations, sexual dysfunction, depression, disinhibition, and withdrawal 
symptoms (Cohen & Rosenbaum, 1987; Ford & Law, 2014; Johnson & Streltzer; 2013). Despite 
clinical and experimental evidence that benzodiazepine use, especially prolonged use, is 
associated with numerous physiological and behavioral risks, little is known about how risky 
choice is affected by short- or long-term benzodiazepine use. 
Chlordiazepoxide  
Chlordiazepoxide (CDP) is a low- to medium-potency benzodiazepine with a relatively long 
half-life of 5 to 30 hours (Griffin et al., 2013). CDP is metabolized into desmethyldiazepam, 
which has a longer half-life of 40-120 hours, and oxazepam, which has a shorter half-life of 5-15 
hours (Griffin et al., 2013). CDP’s intermediate potency and long duration of action make it an 
ideal compound for experimental studies that test a range of doses in relatively long experimental 
sessions. CDP has been shown to produce numerous behavioral effects in rats, including 
increased social behavior, impaired acquisition of novel behavior, increased punished 
responding, increased aggression, and increased impulsivity (Bonuti & Morato, 2018; Carinal et 
al., 2000; Evenden & Ko, 2005; Manzo et al., 2015; McMillan & Leander, 1978; Miczek & 
Barry, 1977; Pitts et al., 2006). 
Statement of the Problem 
Risky choice is an important aspect of many forms of problematic behavior. Probability-
discounting procedures are well-established as an effective and efficient means of assessing risky 
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choice. Benzodiazepines are a commonly prescribed class of drugs that are known to alter 
decision-making, yet little is known about their effects on probability discounting. To date, no 
experimental studies have analyzed how prolonged exposure to benzodiazepines affects 
probability discounting, or how tolerance to acute or chronic effects develop over time. 
Chlordiazepoxide is a benzodiazepine with a long duration of action that produces effects typical 
of the benzodiazepine drug class. The present study assessed how risky choice in a probability-
discounting procedure is affected by acute and chronic exposure to chlordiazepoxide, as well as 
how tolerance to any such effects develops.  
Method 
Overview 
The experiment began with lever-press training in which food-pellets were initially 
delivered on a continuous schedule of reinforcement (each response on either lever produced 
food), and then on a probabilistic schedule of reinforcement (each response on either lever had a 
50% chance of producing food). Next, a probability-discounting procedure was implemented in 
which a choice between a single food pellet delivered with 100% probability or three food pellets 
delivered with one of five probabilities (100%, 50%, 25%, 12.5%, 6.25%) was available. The 
probability of the larger reinforcer being delivered decreased across blocks of trials within each 
session, and sessions were conducted until stable responding was observed (e.g., St. Onge et al., 
2010).  
Once stability was observed, rats were administered acute doses of CDP and tested using 
the same probability-discounting procedure. The acute-exposure phase of the study allowed for 
observation of how short-term exposure to CDP affected risky choice. Once all rats had received 
each acute dose at least twice, chronic CDP exposure began. Chronic exposure consisted of daily 
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injections of an intermediate dose (10.0 mg/kg) of CDP for a minimum of 30 days, depending on 
stability of responding. Following chronic exposure, the procedure from the acute phase of the 
study was repeated with the caveat that the chronic dose was administered every day that acute 
doses were not. This replication of the acute phase of the study during chronic exposure allowed 
for observation of how chronic exposure to CDP affected risky choice over time, as well as how 
tolerance to risky-choice-altering effects of CDP developed. 
Subjects 
Eight experimentally naïve male Sprague-Dawley rats served as subjects during the acute 
phase of the study. Two rats died due to unrelated health issues during the chronic-exposure 
phase, leaving six rats for the remainder of the study. All rats were pair-housed in controlled 
environmental conditions (temperature, 24°C; 12-h reverse light/dark cycle), with continuous 
access to water in home cages. Sessions were conducted at approximately the same time each 
day, five days per week (Monday-Friday). Rats were fed approximately 13 g of food 
approximately 30 min following sessions, resulting in approximately 22 h of food restriction 
prior to each experimental session. 
Apparatus 
Sessions were conducted in eight standard operant-conditioning chambers for rats, each 
enclosed in a melamine sound-attenuating cubicle (Med Associates, VT). Each chamber 
contained a working area of 30.5 cm by 24.5 cm by 21.0 cm, a grid floor, and a 45-mg pellet 
dispenser with a pellet receptacle centered between two retractable response levers. Levers were 
11.5 cm apart from each other and required at least 0.25 N of force for a response to be recorded.  
Levers were 4.8 cm wide, protruded 1.9 cm into the chamber, and were elevated 8 cm from the 
grid floor. Two 28-V stimulus lights, 2.5 cm in diameter, were approximately 7 cm above each 
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lever. Each chamber had a 28-V houselight on the wall opposite to the working wall, and a 
ventilation fan to circulate air and to mask extraneous noise. Data collection and programmed 
consequences were controlled by a personal computer equipped with Med-PC software (Med 
Associates, VT). 
Drugs 
Chlordiazepoxide hydrochloride (CDP, Sigma, St. Louis MO; 7-Chloro-2-
(methylamino)-5-phenyl-3H-1, 4-benzodiazepine 4-oxide hydrochloride) was dissolved in 0.9% 
sodium-chloride solution on test days. Extra solution was stored in a refrigerator to prevent 
hydrolysis (Vinkers et al., 2010). CDP and its vehicle control (saline) were administered at a 
volume of 1 ml/kg intraperitoneally 15 minutes prior to the start of experimental sessions. 
Dosing and preparation procedures were adapted from previous research with CDP and operant 
behavior in rats (van Haaren & Anderson, 1998; van Haaren, Katon, & Anderson, 1997). 
Procedure  
Lever-press Training  
At the beginning of each lever-press training session, both levers extended into the 
chamber and food pellets were delivered on a conjoint variable-time (VT) 60 s fixed-ratio (FR) 1 
schedule of reinforcement. On this schedule, a food pellet was delivered an average of once 
every 60 s independent of responding, and immediately following any lever-press response. 
Lever pressing did not affect delivery of pellets from the VT component of the schedule and each 
of these sessions terminated following 60 food-pellet deliveries. If lever pressing had not been 
acquired after five sessions, it was shaped by reinforcement of successive approximations. After 
lever-press acquisition, an FR 1 schedule of reinforcement alternating between levers was 
implemented. Alternating FR 1 sessions consisted of one lever extending into the chamber with a 
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cue light illuminated over it. A response on this lever resulted in the delivery of a single food 
pellet. The FR 1 contingency and cue light alternated between the left and right levers after every 
five responses. Alternating FR 1 sessions continued until lever pressing was consistent on both 
levers and each session terminated after the delivery of 40 food pellets. 
Probabilistic-Reinforcement Training  
After lever-press training was completed, probabilistic reinforcement training began 
(adapted from Ozga & Anderson, 2018). These sessions consisted of 90 trials each, and trials 
were presented every 40 s. Each trial consisted of a single, randomly determined lever being 
extended into the chamber for 10 s, and a response on this lever produced a single food pellet 
with 50% probability. Probabilistic-reinforcement training continued for a minimum of five 
sessions, and until fewer than 10 trials were omitted across three consecutive sessions.  
Probability-Discounting Procedure 
The probability-discounting procedures used in this study were based on those described 
in the work of Floresco et al. (2008). After probabilistic-reinforcement training was complete, 
the probability-discounting procedure was in effect for the remainder of the study. During the 
probability-discounting procedure, one lever was associated with a small/certain reinforcer and 
the other with a large/risky reinforcer. The position of the lever associated with each reinforcer 
was counterbalanced across rats and remained constant throughout the study. Each session began 
with a 10-minute blackout period followed by five blocks of trials, with 16 forced-choice and 
eight free-choice trials in each block. The probability of the large/risky reinforcer was 100% in 
the first block, and then decreased across blocks (100%, 50%, 25%, 12.5%, and 6.25%). 
In forced-choice trials, a single, randomly determined lever was inserted into the chamber 
and a cue light was illuminated above the lever. A response on the lever produced either a 
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small/certain reinforcer (one food pellet, 100% probability), or a large/risky reinforcer (three 
food pellets, varying probability). Pellet delivery was signaled by flashes of the houselight, with 
a single 0.1-s flash occurring as each pellet was delivered. Levers retracted and a 20-s inter-trial 
interval (ITI) began as soon as the final food pellet was delivered at the end of each trial. To 
ensure that responding was exposed to the probability assigned to the lever that produced the 
large/risky reinforcer in each block, the probability of pellet delivery on each forced-choice trial 
was selected from a pre-determined sampling distribution, such that responses on that lever 
produced reinforcement on exactly one of 16 trials in the 6.25% block (approximately once 
every two blocks), one of eight trials for the 12.5%-probability block, two of eight trials in the 
25%-probability block, and four of eight trials in the 50%-probability block. Additionally, 
forced-choice trials were presented quasi-randomly such that a given lever would be presented 
on no more than two consecutive trials unless the other lever had already been presented eight 
times in each block of forced-choice trials. 
In each block, 16 forced-choice trials were followed by eight free-choice trials.  Free-
choice trials consisted of both levers extending into the chamber with a cue light illuminating 
each. A response on either lever resulted in both levers being retracted, both cue lights being 
extinguished, and delivery of the reinforcer associated with the lever upon which the response 
occurred. A response on the lever associated with the small/certain reinforcer produced a single 
pellet and a 0.1-s flash of the houselight, and a response on the lever associated with the 
large/risky reinforcer produced four pellets and four flashes of the houselight, delivered with the 
programmed probability. Unlike forced-choice trials, probabilities for the large/risky reinforcer 
were independent for each trial, such that the probability of food-pellet delivery on a given trial 
was not affected by the outcome of preceding trials. After food-pellet delivery, a 20-s ITI began. 
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If no response was made within 10 s of the beginning of a forced- or free-choice trial (an 
omission), the lever(s) would retract, cue lights would extinguish, and the 20-s ITI began. 
Sessions terminated after 120 total trials (80 forced-choice and 40 free-choice), or 60 min 
(including the 10-min blackout at the start of sessions), whichever occurred first.  
Baseline  
The baseline phase of the study consisted of a minimum of 20 sessions of probability 
discounting, with stability observed for all rats after no more than 21 days. Baseline responding 
was considered stable when the following criteria were met across five consecutive sessions: A 
two-way analysis of variance (ANOVA) showed a main effect of block and neither a main effect 
of session nor a session-by-block interaction, and visual inspection revealed no increasing or 
decreasing trends in the total percentage of responses for the large/risky reinforcer, and a 
minimum of 80% of responses (seven out of eight free-choice trials) for the large/risky reinforcer 
in the first free-choice block (when both reinforcers were delivered with 100% probability).  
Acute Chlordiazepoxide Administration  
Once baseline responding reached stability, the same procedures used to establish 
baseline probability-discounting functions were used to test effects of CDP and its vehicle 
control (saline), with sessions conducted five days per week. CDP (1, 3, 10, 17, and 30 mg/kg) or 
saline was administered to all rats on Tuesdays and Fridays to determine acute effects on 
probability discounting and the relation between different doses and changes in risky choice 
(dose-response function). Control sessions occurred on Mondays and Thursdays, with 
Wednesday sessions being identical to control sessions.  
Drug administration occurred only if the previous (control) day’s larger-reinforcer choice 
in the first block was 80% or greater, and if the overall percent larger-reinforcer choices was 
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within the range of the last five baseline sessions. For any test day on which drug-administration 
criteria were not met, those sessions were identical to control sessions and testing did not resume 
until drug-administration criteria were met. Vehicle was administered prior to drug 
administration in order to allow for habituation to the injection procedure and to determine any 
vehicle-induced effects on behavior.  
Drug doses were administered in both ascending and descending sequences, with an 
additional administration of vehicle occurring between each sequence. Each dose of CDP was 
tested at least twice, with four rats starting with the highest dose and four rats starting with the 
lowest dose. Additional doses were administered if high variability in larger-reinforcer choice 
was observed on drug-administration days (see Table 1 for the number of administrations of each 
dose in each phase). The 17.0 and 30.0 mg/kg doses were administered fewer times because of 
increased omissions following initial administration of these doses (see Table 2 for the number 
of omissions at each dose in each phase).  
Chronic Chlordiazepoxide Exposure 
Following acute drug administration, CDP was  administered daily. The 10.0 mg/kg dose 
was selected for chronic exposure because it was an intermediate dose that produced changes in 
larger-reinforcer choice without producing excessive omissions during the acute phase. 
Probability-discounting sessions were conducted seven days per week, with chronic CDP doses 
administered 15 minutes prior to each session. Daily doses of 10.0 mg/kg CDP continued for a 
minimum of 30 sessions (M = 56.4) and until choice was stable. Stability was determined using 
the same criteria as the acute phase. Due to health issues that disrupted responding, responding 
for one rat required 97 days to reach stability.  
Chronic Dose-Response Determination  
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Once responding was stable after at least thirty days of daily injections of 10.0 mg/kg 
CDP, the dose-response function was re-determined using the same procedures as in the acute 
phase of the study. Daily doses were administered at the same time of day as in the chronic 
dosing phase, and all doses were administered to each rat 15 minutes prior to sessions.  If drug-
administration criteria were not met on control days, the 10.0 mg/kg dose was still administered 
on test days (see “Acute chlordiazepoxide administration,” above). The same range of doses 
were administered as in the acute phase to allow for comparisons of dose-response functions 
from before and after chronic exposure. 
Data Analysis 
In general, data analysis consisted of four categories of comparisons. First, data from acute 
test days were compared to determine how behavior changed following injections of either saline 
or the range of CDP doses (i.e., acute dose-response function). Next, data from the first and last 
five days of the chronic-exposure phase were used to compare how behavioral measures changed 
as a function of chronic exposure to a single dose of CDP (10.0 mg/kg). Note that although this 
phase is referred to as the chronic-exposure phase, chronic exposure continued into the final 
phase of the study. In the final phase of the study, chronic injections of 10.0 mg/kg continued but 
the full range of CDP doses were substituted on test days. Data from these test days were used to 
compare changes in behavior following injections of either saline or the range of CDP doses in 
the context of chronic exposure (i.e., chronic dose-response function). Finally, data from the 
acute and chronic dose-response functions were compared to assess how CDP’s effects on 
behavior changed as a function of chronic exposure.  
Dependent measures  
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Dependent variables included percent larger-reinforcer choice, indifference points (IPs), 
area under the curve (AUC), win-stay ratios (WSRs), and lose-shift ratios (LSRs). Percent larger-
reinforcer choice was calculated block-by-block by dividing the number of free-choice trials in 
which the larger reinforcer was selected by the total number of free-choice trials per block. A 
session-by-session measure of percent larger-reinforcer choice was also calculated by dividing 
the number of responses for the larger reinforcer during free-choice trials by the total number of 
free-choice trials in a session. IPs were calculated by fitting a regression line to obtained data and 
interpolating the probability at which choice for both reinforcers was equivalent.  
To calculate AUC, probability of delivery was converted to “odds against delivery” by 
determining the average number of unreinforced responses required before a reinforcer would be 
delivered. For example, a 25% probability of delivery was converted to an odds-against value of 
three because three unreinforced responses, on average, would occur before a reinforcer would 
be delivered. Percent larger-reinforcer choice was plotted as a function of odds-against values 
and vertical lines were drawn from each data point to the x-axis of the graph. Doing so created 
four trapezoids under the discounting curve that were summed to determine the total area of the 
graph beneath the curve. AUC was expressed as the proportion of the entire graph area 
consumed by the trapezoids. 
WSRs and LSRs were calculated by identifying whether a response was made for the 
small/certain or large/risky reinforcer during free-choice trials, and whether the prior response 
resulted in food-pellet delivery (a “win” or “loss”). Win-stay ratios consisted of the number of 
responses for the large/risky reinforcer during free-choice trials that followed a “win” divided by 
the total number of responses that resulted in a “win.” Essentially, WSRs were the proportion of 
trials that followed a “win” on which responding stayed allocated toward the large/risky 
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reinforcer. Lose-shift ratios consisted of the number of responses for the small/certain reinforcer 
that followed a loss divided by the total number of responses that resulted in a “loss.” 
Essentially, LSRs were the proportion of trials that followed a “loss” on which responding 
shifted away from the large/risky reinforcer. Omission frequency was also recorded and analyzed 
as a secondary dependent variable.  
Acute Chlordiazepoxide Administration  
Dose-response functions for percent larger-reinforcer choice, IP and AUC were determined 
and visually analyzed. Overall percent larger-reinforcer choice and AUC were expected to 
increase dose-dependently. Changes in these variables was assessed for statistical significance 
with a series of repeated-measures analyses of variance (ANOVAs) and paired-samples t-tests. 
Chronic Chlordiazepoxide Exposure 
To assess changes in percent larger-reinforcer choice, IPs, AUC, WSRs, and LSRs as a 
function of chronic drug exposure, data from the first and last five days of the chronic phase 
were graphed for visual analysis. Statistical significance was assessed using repeated-measures 
ANOVAS and paired-samples t-tests. Two rats died during the chronic-exposure phase of the 
study. Therefore, all analyses of chronic drug effects and comparisons of acute and chronic 
effects utilized a total of six rats.  
Chronic Dose-Response Determination  
The same measures used in the acute phase were assessed after chronic CDP exposure using 
visual analysis, repeated-measures ANOVAs, and paired-samples t-tests. Acute and chronic 
effects were also compared to one another using visual analysis, repeated-measures ANOVAs, 
and paired-samples t-tests. Due to a global pandemic, laboratory facilities were closed prior to 
the completion of the final dose-response determination. Complete data sets were collected for 
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Figure 1 displays the mean percent larger-reinforcer choice for all rats (N = 8) during each 
trial block under saline, 1.0, 3.0, and 10.0 mg/kg CDP. Note that data for the acute 17.0 and 30.0 
mg/kg doses were omitted from all analyses because those doses disrupted magnitude 
discrimination and increased trial omissions (see Table 1). Under saline, percent larger-reinforcer 
choice decreased as a function of probability of delivery, indicating that responding was sensitive 
to the programmed contingencies [F(2.04) = 123.40, p < .01].  
Acute Percent Larger-Reinforcer Choice 
Figures 1 and 2 show percent larger-reinforcer choice as a function of probability of 
delivery for group and individual means, respectively. CDP increased percent larger-reinforcer 
choice relative to saline [F(3) = 4.57, p = .01], particularly in the final three blocks, which 
indicates increased risky choice. This effect was most pronounced at the 3.0 and 10.0 mg/kg 
doses (see Figure 3). Pairwise comparisons indicated that 3.0 mg/kg CDP (M = 60.42, SE = 4.78, 
p < .01) and 10.0 mg/kg CDP (M = 65.83, SE = 3.92, p = .02)  significantly increased percent 
larger-reinforcer choice relative to saline, although 1.0 mg/kg CDP also increased percent larger-
reinforcer choice in the third block.  
A significant dose x block interaction was observed [F(3.49) = 2.58, p = .02], indicating that 
CDP increased percent larger-reinforcer choice in some blocks more than others. To further 
elucidate CDP’s effects on percent larger-reinforcer choice at the block-by-block level, a series 
of paired-samples t-tests were conducted. Statistically significant increases in percent larger-
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reinforcer choice occurred primarily in the third block. At the 1.0 mg/kg dose, percent larger-
reinforcer choice was significantly higher in the third block, t(7) = 3.38,  p = .01, relative to 
saline. At the 3.0 mg/kg dose, percent larger-reinforcer choice was significantly higher in the 
third block as well, t(7) = 4.13, p < .01. At the 10.0 mg/kg dose, larger-reinforcer choice was also 
significantly higher in the third block, t(7) = 3.93, p < .01. An increase in larger-reinforcer choice 
was also observed in the fourth block under 10.0 mg/kg CDP but was not statistically significant. 
See Table 2 for means and SEM for percent larger-reinforcer choice during each block at each 
dose.  
AUC, IPs, WSRs, and LSRs 
 Figure 4 displays mean AUC under saline and each dose of CDP. CDP significantly 
increased AUC relative to saline [F(3) = 3.61, p = .03], indicating increased risky choice. This 
effect was most pronounced at the 3.0 and 10.0 mg/kg doses. A series of paired-samples t-tests 
were conducted to examine changes in AUC at each dose of CDP relative to saline. AUC was 
significantly higher under 3.0 mg/kg CDP [t(7) = 3.52, p = .01] and 10.0 mg/kg CDP [t(7) = 
2.59, p = .04]. There was no statistically significant effect of dose on IPs, WSRs, or LSRs at any 
dose of CDP. See Table 3 for means and SEM for AUC, IPs, WSRs, and LSRs at each dose of 
CDP.  
Omissions 
 Omissions occurred more frequently under CDP than saline during acute drug exposure 
(see Table 1). This effect was most pronounced at the 17.0 and 30.0 mg/kg doses. A main effect 
of dose was detected [F(5) = 35.30, p < .001], indicating that omissions occurred more often 
following CDP administration. Post-hoc tests revealed that omissions occurred significantly 
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more often at the 17.0 mg/kg (M = 25.13, SE = 15.48, p = .04) and 30.0 (M = 42.00, SE = 15.47, 
p < .01) mg/kg doses relative to saline (M = 0.34, SE = 0.55).  
Chronic CDP Exposure  
Figure 5 displays mean percent larger-reinforcer choice during each block for the first and 
last five days of the chronic-exposure phase, as well as under saline during baseline. Note that all 
analyses after the initial acute-exposure phase were conducted with a total of six rats (N = 6). 
Percent larger-reinforcer choice increased relative to saline during initial chronic exposure to 
10.0 mg/kg CDP [F(2) = 4.41, p = .04] but subsided to near-baseline levels by the final five days 
of chronic exposure. IPs, AUC, WSRs and LSRs were not significantly different from baseline at 
either the beginning or the end of the chronic-exposure phase (see Figures 6-8). See Table 4 for 
means and SEM for all dependent measures during the first and last five days of the chronic-
exposure phase, as well as under saline.  
Chronic Percent-Larger Reinforcer Choice 
Figure 9 shows percent larger-reinforcer choice as a function of probability of delivery at 
each dose of CDP during chronic drug exposure. Note that the 17.0 and 30.0 mg/kg doses are 
included in the figure, as once tolerance to CDP developed these doses no longer suppressed 
responding after rats had been exposed to chronic CDP. CDP increased percent larger-reinforcer 
choice relative to saline, F(5) = 11.37, p < .01, indicating an increase in risky choice. This effect 
was most pronounced at the higher doses (10.0, 17.0, and 30.0 mg/kg).  Pairwise comparisons 
revealed a statistically significant effect of CDP relative to saline (M = 41.58, SE = 3.77) at the 
10.0 (M = 59.75, SE = 2.54, p < .01), 17.0 (M = 57.00, SE = 3.46, p = .03), and 30.0 (M = 62.75, 
SE = 4.50, p < .01) mg/kg doses. This effect was most pronounced in the third block (see Figures 
9 and 10). 
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A significant dose x block interaction was observed, F(20) = 4.25, p < .01, indicating that 
CDP increased percent larger-reinforcer choice in some blocks more than others. To further 
elucidate CDP’s effects on percent larger-reinforcer choice at the block-by-block level, a series 
of paired-samples t-tests were conducted. At this level of analysis, percent larger-reinforcer 
choice was significantly higher only at the 30.0 mg/kg, and only in the third block. Visual 
analysis of Figures 9 and 10 suggests that 10.0 and 17.0 mg/kg also increased percent larger-
reinforcer choice in the third block.  
Figure 10 shows mean percent larger-reinforcer choice as a function of probability of 
delivery for individual rats during chronic drug exposure. CDP increased larger-reinforcer choice 
for most rats, except for Rat 4. For Rat 4, larger-reinforcer choice was highest under saline and 
decreased when CDP was administered. Larger-reinforcer choice under saline for Rat 4 was also 
relatively higher than for other rats. This baseline-dependent pattern of responding was only 
evident during chronic drug exposure, and only for the one rat.  
Chronic AUC, IPs, WSRs, and LSRs 
Figures 11 and 12 show AUC and IPs, respectively, as a function of drug dose. AUC was 
higher under CDP relative to saline, indicating increased risky choice, but this increase was not 
statistically significant. IPs were also higher at each dose of CDP relative to saline, indicating 
increased risky choice. This effect was statistically significant [F(5) = 5.32, p < .01], and 
pairwise comparisons revealed a statistically significant effect at the 30.0 mg/kg dose [t(4) = 
3.52, p =.04]. There was no significant effect of CDP on WSRs or LSRs. 
Chronic Omissions 
During chronic exposure to 10.0 mg/kg CDP, higher doses of CDP (17.0 and 30.0 mg/kg) 
did not significantly increase the number of omissions (see Table 1). In the context of chronic 
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exposure, omissions were significantly more frequent under saline (M = 2.43, SE = 0.54, p = 0.1) 
than 10.0 m/kg CDP (M = 0.15, SE = 0.15). 
Acute vs Chronic Comparisons 
Figure 13 shows percent larger-reinforcer choice as a function of probability of delivery for 
saline during acute and chronic drug exposure. Percent larger-reinforcer choice under saline did 
not change significantly as a function of chronic CDP exposure, indicating that risky choice 
returned to baseline levels when chronic doses were replaced with saline. Figure 14 shows 
percent larger-reinforcer choice as a function of drug dose during acute and chronic drug 
exposure. Note that higher doses of CDP were required to reach the same levels of larger-
reinforcer choice seen during the acute phase (a rightward shift from the acute curve to the 
chronic curve), but this effect was not statistically significant. Across doses, omissions were less 
frequent during chronic drug exposure, F(1) = 23.85, p < .01 (see Table 1). CDPs effects on 
AUC, IPs, WSRs and LSRs did not change significantly as a function of chronic exposure.  
Discussion 
 The present study was designed to assess how CDP might affect risky choice in a 
probability-discounting procedure. The procedure used in the present study was an effective tool 
to assess changes in risky choice following acute and chronic administration of CDP. Under 
baseline conditions, responding was sensitive to the programmed contingencies and larger-
reinforcer choice decreased as a function of probability of delivery. During acute drug exposure, 
CDP dose-dependently increased larger-reinforcer choice, i.e., risky choice.  
After chronic drug exposure, larger-reinforcer choice returned to baseline levels and 
higher doses of CDP were required to increase larger-reinforcer choice, indicating tolerance to 
CDP’s effects. The highest doses of CDP (17.0 and 30.0 mg/kg) produced excessive omissions 
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in the acute phase but not after chronic drug exposure, providing further evidence for the 
development of tolerance. The development of tolerance to CDP’s effects stands in accordance 
with prior research on tolerance to certain effects of benzodiazepines (e.g., Bourin, 2019; 
Gravielle, 2016; Johnson & Streltzer, 2013; McMillan & Leander, 1978; Potts & Krishnan, 
1992; Rosenberg & Chiu, 1985; Sannerud et al., 1993). However, the results of the present study 
are the first to demonstrate tolerance to CDP’s effects on risky choice. 
Clinical Implications for Tolerance 
 Development of tolerance to CDP-induced increases in risky choice may be 
advantageous from a clinical perspective. Acute exposure to CDP has been previously shown to 
increase risky choice in several experimental paradigms and is associated with increases in a 
variety of maladaptive behaviors (Daderman, 2005; Daderman & Edman, 2001; Daderman et al., 
2002; Deakin et al., 2004; Lane et al., 2005; 2008; Leung, 2011; Orriols et al., 2011; Pajunen et 
al., 2017; Simoes et al., 2009, Van der Sluiszen et al., 2017). Results of the present study suggest 
that increases in risky choice may not persist indefinitely, and that individuals prescribed CDP 
for long periods of time may not continue to engage in increased risky choice. This could be 
particularly beneficial given that there is little evidence that tolerance to the anxiolytic effects of 
CDP develops in humans (for reviews, see Hood et al., 2012; Vinkers & Olivier, 2012). 
Although the development of tolerance observed in the present study may be beneficial 
from a clinical perspective, increases in risky choice prior to the development of tolerance would 
not be. CDP increased risky choice during the acute-exposure phase and at higher doses after 
chronic exposure. These findings add to the existing literature that CDP increases risky choice, 
although the present findings are the first to demonstrate an increase in risky choice in a 
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probability-discounting procedure and to show the development of tolerance to such effects 
(Deakin et al., 2004; Lane et al., 2005; 2008).  
GABA, Risky Choice and Schizophrenia 
Because CDP is a GABA agonist, the present data support the notion that the GABA system 
may be an important factor in risky choice. These results are in line with prior research that has 
demonstrated that the GABA system is involved in risky choice (Bidwell et al., 2013; Murphy et 
al., 2012; Paine, et al., 2011; Schindler, et al., 2014; Ucha et al., 2019). These results also 
demonstrate that effects of CDP on risky choice are similar to those of ethanol, which also acts 
on the GABA system (Wallin-Miller et al., 2017).  
The GABA system may interact with risky choice in several ways. Disruption of GABA 
receptors (reduced GABA transmission) in the prefrontal cortex of rats has been shown to 
increase reward sensitivity but reduce risky choice (Piantadosi et al., 2016). While reward 
sensitivity (as measured by WSRs) was not altered in the present study, benzodiazepines have 
been shown to alter GABA activity in the prefrontal cortex and associated behavioral outcomes 
(e.g., Dominguez et al., 2018; Lissek et al., 2017). GABA disruption in the prefrontal cortex has 
also been associated with increased omissions in choice procedures and spatial discrimination 
errors in radial-maze tasks (Auger & Floresco, 2014; Paine et al., 2011; 2015, Piantadosi & 
Floresco, 2014). Such disruptions may explain why an increased number of omissions were 
observed under saline during the chronic-exposure phase of the present study. That is, chronic 
exposure to CDP likely resulted in decreased responsiveness of the GABA system, at which 
point administration of saline instead of the chronic dose of CDP could have caused a deficit in 
GABA signaling (e.g., Allison & Pratt, 2003; Bateson 2002).  
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Disrupted GABA signaling may be related to some of the symptoms seen in psychiatric 
disorders such as schizophrenia. Deficits in attention, working memory, impulse control, 
discrimination of conditioned fear signals, cue salience, and decision-making are features of 
impaired GABA functioning that share some similarities with symptoms of schizophrenia (e.g., 
Auger & Floresco, 2014; Kim et al., 2009; Lissek et al., 2017; Paine et al., 2011; 2015; Piandosi 
& Floresco, 2014; Piandosi et al., 2016; Shurman et al., 2005). The results of the present study 
provide further evidence that the GABA system may be an attractive target for research on 
pharmacological treatments for symptoms of disorders such as schizophrenia.  
Delay and Probability Discounting 
The current study adds to the body of evidence that pharmacological manipulations can 
produce differential results in delay- and probability-discounting procedures. Prior research on 
benzodiazepines and delay discounting has been mixed. In one procedure, flunitrazepam 
decreased delay discounting (decreased impulsive choice) in pigeons at all delay values 
(Eppolito et al., 2011). In a study with Lewis and Fischer 344 with rats, low doses of diazepam 
increased delay discounting while higher doses decreased delay discounting for Fischer 344 rats 
but had no effect on Lewis rats (Huskinson & Anderson, 2012). On the other hand, diazepam has 
not produced changes in measures of delay discounting in rhesus monkeys or humans (Maguire 
et al., 2012; Reynolds et al., 2004). In contrast, CDP consistently and dose-dependently 
increased larger-reinforcer choice in the present study.  
Measurement 
The present study employed several measures, some of which were selected because of their 
utility in delay-discounting procedures. Percent larger-reinforcer choice, a direct measure of 
responding, is based only on the assumption that changes in larger-reinforcer choice indicate 
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changes in risky (or impulsive) choice. This assumption is accepted at all delay values in delay 
discounting because it is always advantageous to choose the larger reinforcer, and choosing the 
smaller reinforcer is always considered impulsive. In probability discounting, however, choosing 
the larger reinforcer is advantageous only when the probability of delivery is relatively high. 
Thus, increases in larger-reinforcer choice are only said to reflect increased risky choice when 
the odds of delivery are relatively low. Therefore, measures based on whole-session responding 
(high- and low-probability trials) may not reflect risky choice as accurately as block-by-block 
measures.  
Whole-Session Measures 
AUC and IPs appeared to be less sensitive than percent larger-reinforcer choice as 
measures of risky choice. Although AUC and IPs are derived from larger-reinforcer choice, they 
are calculated using whole-session responding rather than block-by-block responding. Changes 
in larger-reinforcer choice that occurred at lower probabilities (i.e., the third, fourth, and fifth 
blocks) may not have been large enough to significantly increase AUC and IPs in most cases. 
While these measures are commonly used in delay-discounting studies, they may not be 
appropriate for analyzing probability-discounting data. 
AUC and IPs should be interpreted with caution for several reasons. In the present study, 
changes in responding in the first two blocks do not indicate changes in risky choice yet are 
factored into the calculation of AUC and IPs. Additionally, larger-reinforcer choice in the first 
two blocks was often at or near 100%. Thus, increases in larger-reinforcer choice in later blocks, 
while significant on their own, may not have been large enough to produce a significant change 
in overall AUC or IPs.  
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Although AUC and IPs may not adequately characterize risky choice in probability-
discounting procedures, these measures do have one advantage over percent larger-reinforcer 
choice. AUC and IPs take into account the relative differences in probability of delivery for each 
block. For example, the portions of the graph that are summed to calculate AUC become larger 
as the odds against delivery become greater (as probability of delivery decreases). This means 
that an increase in larger-reinforcer choice in the final block would increase the overall AUC 
more than an identical increase in larger-reinforcer choice in the first block. Similarly, the 
regression line that is fitted to raw data and used to interpolate IPs weights changes in larger-
reinforce choice more heavily as the odds against delivery increase.  
Block-by-Block Measures 
Block-by-block measures of risky choice (i.e., larger-reinforcer choice) were most 
sensitive to CDP’s effects, but did not take into account changes in the risk associated with 
larger-reinforcer choice across blocks. Changes in larger-reinforcer choice were most evident in 
the third trial block, with clear increases also observed in the fourth, and to a lesser extent, fifth 
blocks. In the third block, the probability of delivery was 25%. Over repeated trials, this response 
option would yield an average of 0.75 pellets/response (compared to 1.0 pellet/response for the 
small/certain option across all blocks). The difference in average yield between the two response 
options was smallest in the third block with a difference of 0.25 pellets/response. As the 
difference in average yield between the response options increased across blocks, CDP’s effect 
on larger-reinforcer choice became smaller and smaller. This suggests that as the discriminability 
of the two contingencies in each block increased, larger-reinforcer choice was less sensitive to 
CDP’s effects.  
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In the fifth block, with a very low probability of reinforcer delivery and an average 
larger-reinforcer yield of only 0.19 pellets/response, responding for the large/risky reinforcer was 
rarely reinforced. Considering the low rates of responding and the equally low probability of 
reinforcement in this block, increases in percent larger-reinforcer choice may carry more 
theoretical weight (i.e., be considered riskier) than in other blocks with higher rates of 
reinforcement (Yates, 2019). That is, it is possible that the disparity in average larger-reinforcer 
yield became more and more discriminable as the probability of reinforcer delivery decreased 
across blocks. Therefore, increases in larger-reinforcer choice during the final block may reflect 
a stronger effect than a similar increase in prior blocks.   
Individual Differences 
Behavior analysis is rooted in single-subject experimental designs, yet discounting research 
often employs group designs (Sidman, 1988). In the present study, larger-reinforcer choice for 
Rat 1 was increased to nearly 100% by the 10.0 mg/kg acute dose across all blocks. This extreme 
increase in later blocks was not evident in any other doses or rats. This pattern continued during 
the chronic phase to a lesser extent, with larger-reinforcer choice for Rat 1 consistently higher 
than for any other rats in the third block. It is unclear what may have caused this individual 
difference in responding.  
A baseline-dependent effect appears to have occurred for one rat during chronic exposure. 
Larger-reinforcer choice for Rat 4 was consistently higher than for all other rats under saline, and 
contrary to its effect on responding for all other rats, larger-reinforcer choice was decreased 
following CDP administration. It is worth noting that during the chronic phase of this 
experiment, rats had been receiving daily doses of 10.0 mg/kg CDP for at least 50 days. 
Therefore, increases in larger-reinforcer choice relative to 10.0 mg/kg are a more relevant 
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indicator of CDP’s effects. Nonetheless, for all other rats, larger-reinforcer choice was decreased 
by saline administration and decreased by CDP administration in the chronic phase.  
Limitations and Future Directions 
There were several limitations to the present study. During the acute-exposure phase, each 
rat received each dose of CDP at least twice. However, due to unforeseen emergent 
circumstances, data collection was concluded before the same number of data points could be 
acquired for each dose after chronic drug exposure. Furthermore, two rats died at the beginning 
of the chronic-exposure phase, leaving the total number of rats available for cross-phase 
comparisons at six. Undoubtedly, the reduced number of data points and the overall reduced 
sample size reduced the statistical power of all analyses conducted after the acute phase. This 
lack of power may have contributed to the apparent lack of significant effects of CDP on some 
measures, such as AUC and IPs. Despite these limitations, the present study provides evidence 
that CDP increases risky choice, and that tolerance to this effect develops over time.  
Another limitation to the present study was that all the rats used as subjects were male. Prior 
research has demonstrated sex-specific differences in baseline decision making, as well as sex-
dependent drug effects. Ethanol, a GABA agonist, has been shown to increase risky choice in 
male rats, but not females (Wallin-Miller et al., 2017). Interestingly, a separate study 
demonstrated that testosterone may alter risky choice in males by increasing loss aversion and 
decreasing reward sensitivity (Wallin-Miller et al., 2015). Taken together, these findings indicate 
that there may be significant sex-specific differences in risky choice both before and after 
exposure to GABA agonists. Such differences limit the generality of the present study’s findings.  
Future research should consider how different manipulations of probability and reinforcer 
magnitude affect risky choice. The present study used one- and three-pellet reinforcer 
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magnitudes for the small/certain and large/risky response options, respectively. Prior studies 
have used a variety of reinforcer magnitudes, with varying discrepancies between the 
small/certain and large/risky options (e.g., Bidwell et al., 2013;  St. Onge et al., 2010; Yates, 
2019). It is unknown how changes in reinforcer discrepancy affect risky choice. Similarly, the 
present study used a range of probabilities that differed from previous research. Prior studies 
have employed several various ranges of probabilities (e.g., 100/66/33/16.5%, 100/50/25/0%), 
often in combination with larger-reinforcer magnitudes that result in only the block with the 
lowest probability providing a risky choice (i.e., a choice involving a large/risky response option 
with a lower average yield than the small/certain option). The present study included three 
blocks with probabilities in which, given the three-pellet reinforcer magnitude, larger-reinforcer 
choice was considered risky. Further research should elucidate how different combinations of 
reinforcer magnitude and probability of delivery affect risky choice. 
In the present study, larger-reinforcer choice was optimal (not risky) in the first two blocks. 
While the first (100%) block served the purpose of ensuring that responding discriminated 
between the larger and smaller reinforcers when probability of delivery was equal, the second 
(50%) block served no such purpose. Future research should assess the effects and utility of 
including multiple probabilities at which choice for the larger reinforcer is optimal. It is possible 
that including multiple blocks without risky options could affect responding in later blocks with 
riskier response options. In either case, including more than a single block with a high 
probability of reinforcer delivery may not be necessary.  
Because the relative riskiness of larger-reinforcer choice changes with different 
probabilities of delivery, a measure that accounts for relative risk but excludes responding at 
high probabilities of delivery could prove useful. Probability-discounting procedures represent a 
CHLORDIAZEPOXIDE INCREASES RISKY CHOICE  33 
relatively new behavioral paradigm that is distinct from delay discounting. While some of the 
structural features of delay-discounting procedures have been useful in developing probability-
discounting procedures, measures and methods of data analysis unique to probability discounting 
are needed (e.g., Green & Myerson, 2019; Yates, 2019). Still, modern probability-discounting 
research has yet to employ novel measures of probability discounting (e.g., Islas-Preciado et al., 
2020; Ozga & Anderson, 2019; Yates et al., 2019).  
A novel measure for probability discounting would need to address several issues. First, an 
improved measure of probability discounting should weight greater amounts of risk (i.e., lower 
probabilities of delivery) more heavily than lesser amounts of risk. Secondly, such a measure 
should exclude any trial blocks in which the expected value of the larger reinforcer is equal to or 
greater than that of the smaller reinforcer. For example, an economist might define risk as the 
difference between optimal and obtained outcomes in a choice scenario (Keeney & Raiffa, 
1993).  
In the present study, risk could be conceptualized as the difference in average yields 
between the smaller and larger reinforcer at a given probability. A response for the smaller 
reinforcer in the third block has an average yield of 1.0 pellets/response. A response for the 
larger reinforcer in the third block has an average yield of 0.75 pellets/response, so the risk 
associated with larger-reinforcer choice in the third block is (1.0 – 0.75) 0.25. Probability of 
delivery is four times smaller in the fifth block, so the risk is accordingly higher as well at 
0.8125. These measures of risk could then be used to weight a measure such as larger-reinforcer 
choice in statistical analyses. While this measure would need to be adjusted to account for actual 
obtained number of reinforcers and suboptimal responding in baseline, it meets the requirements 
described above and lends itself well to statistical analysis.  
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.  
Although the present study adds to the body of evidence that implicates the GABA system 
in risky choice, changes in GABA were not directly measured. To further clarify the relation 
between benzodiazepines, GABA, and risky choice, GABA receptors could be further 
manipulated. For example, a drug that prevents CDP from increasing GABA activity (a GABA 
antagonist) could be administered. Bicuculline is one such antagonist (for a review of GABA 
antagonists, see Johnston, 2013). Comparisons of risky choice after exposure to CDP in 
combination with bicuculline and exposure to CDP alone could help elucidate effects of CDP 
and the role of GABA in risky choice. This line of inquiry could be further pursued by 
investigating effects of specific subunits of GABA receptors. Although the GABAA subtype is 
thought to be the primary contributor to changes in anxiety and risky choice, GABAA receptors 
can further be divided into six subunits.  
Some subunits of the GABAA receptor are differentially associated with specific 
benzodiazepine effects (for a review, see Sigel & Steinmann, 2012). The α1 subunit is involved 
in sedation and amnesia, while α2 and α3 are involved in anxiolysis. The α5 subunit is associated 
with benzodiazepine-related impairments in learning and memory. It is therefore possible that 
one or more subunits is differentially involved in risky choice. Pharmacological manipulation of 
specific subunits could help to pinpoint with greater specificity the mechanism by which CDP 
and GABA affect risky choice (e.g., Fischer, 2011; Jansen et al., 2008; Schwienteck et al., 2017). 
Such knowledge could also aid in determining the mechanisms by which differential tolerance to 
the therapeutic and iatrogenic effects of CDP develops. 
Future research on probability-discounting and CDP should also investigate the possibility 
of baseline-dependent effects. A baseline-dependent effect was observed for a single rat during 
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one phase of the present study. Because baseline risky choice was otherwise relatively 
homogeneous, it is unclear if this effect would have been more pronounced in a sample with 
varying levels of baseline risky choice. This could be accomplished by assigning animals to 
experimental conditions based on their natural baseline behavior or by artificially inducing 
different baseline behavior through procedural manipulations. A third possibility would be to 
compare CDP’s effects on different strains of rats with different baseline levels of risky choice 
(e.g., Huskinson et al., 2012, Ozga & Anderson, 2018).  
Summary and Conclusions 
As a result of incomplete data collection and reduced statistical power in the present study, 
some of the results should be interpreted with caution. However, there are at least two 
conclusions that can be drawn with relative confidence regarding effects of CDP on risky choice: 
acute administration of CDP dose-dependently increased larger-reinforcer choice and chronic 
exposure to CDP resulted in tolerance to those effects. Furthermore, no changes in WSRs or 
LSRs were observed at any dose of CDP. Therefore, it is unlikely that increases in larger-
reinforcer choice were driven by changes in reinforcer sensitivity or loss sensitivity.  
The results of the present study indicate that further research is necessary to better 
understand how CDP and other benzodiazepines affect complex behavior. While CDP did 
increase larger-reinforcer choice, choosing between smaller/certain outcomes and large/risky 
outcomes is a necessary but not sufficient feature of risky choice in humans (e.g., Green & 
Myerson, 2019). Furthermore, whole-session measures of choice such as AUC and IPs should be 
used with caution as measures risky choice. Although increased risky choice is not a listed side-
effect of benzodiazepines, the present study adds to the body of research indicating that 
benzodiazepines can increase risky choice (e.g., Ahwazi & Abdijadid, 2019). The results of the 
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present study are novel in that they demonstrate that CDP increases risky choice in a probability-
discounting procedure, and importantly that tolerance to this effect develops over time.  
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Table 1 
Mean and SEM for omitted trials at each dose of CDP in each phase. 
N = 8 
 
  
 Dose CDP (mg/kg) 
 Saline 1.0 3.0 10.0 17.0 30.0 
Phase M SEM M SEM M SEM M SEM M SEM M SEM 
Acute 0.34 0.18 0.38 0.15 0.19 0.11 0.85 0.51 25.13 4.73 42.00 5.82 
Chronic 2.43 0.75 6.04 2.58 1.29 0.49 0.15 0.15 2.67 1.30 0.10 0.10 
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Table 2 
Mean and SEM for acute percent larger-reinforcer choice in each block during acute drug 
exposure.  
 Dose CDP (mg/kg) 
 Saline 1.0 3.0 10.0 
Block M SEM M SEM M SEM M SEM 
1 99.48 0.52 100.0 0.00 97.92 1.04 98.44 1.02 
2 85.05 5.14 89.32 5.06 94.01 3.42 90.23 2.73 
3 33.67 6.91 61.20 12.18 71.61 8.09 72.92 8.22 
4 11.33 7.48 19.80 7.03 22.96 9.89 39.97 9.64 
5 7.63 3.23 5.21 3.82 14.58 8.55 24.61 11.02 
N = 8  
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Table 3 
Mean and SEM for area-under-the-curve (AUC), indifference points (IPs), win:stay ratios 
(WSRs) and lose:shift ratios (LSRs) during acute drug exposure.  
 Dose CDP (mg/kg) 
 Saline 1.0 3.0 10.0 
 M SEM M SEM M SEM M SEM 
AUC .24 .04 .31 .05 .38 .07 .46 .07 
IPs 2.55 0.63 4.02 0.82 7.08 2.60 4.86 0.66 
WSRs .65 .02 .63 .02 .63 .03 .60 .03 
LSRs .90 .03 .93 .04 .91 .04 .87 .04 
N = 8  
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Table 4 
Mean and SEM for percent larger-reinforcer choice (% LRC), area-under-the-curve (AUC), 
indifference points (IPs), win:stay ratios (WSRs) and lose:shift ratios (LSRs) during the first and 
last five days of chronic exposure. 
N = 6  
 Condition 
 Saline First Five Last Five 
Measure M SEM M SEM M SEM 
% LRC 45.47 2.33 68.65 5.58 55.97 6.13 
AUC .23 .04 .34 .08 .27 .06 
IPs 2.55 0.63 4.76 1.78 3.24 0.91 
WSRs .65 .18 .61 .02 .61 .01 
LSRs .90 .03 .89 .06 .92 .04 
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Table 5 
Mean and SEM for percent larger-reinforcer choice in each block at each dose of CDP during 
chronic drug exposure.  
N = 6  
 Dose CDP (mg/kg) 
 Saline 1.0 3.0 10.0 17.0 30.0 
Block M SEM M SEM M SEM M SEM M SEM M SEM 
1 100.00 0.00 98.96 1.04 98.96 1.04 100.00 0.00 98.96 1.04 100.00 0.00 
2 80.90 10.13 83.33 7.85 92.71 6.13 97.92 1.32 97.92 1.32 96.25 2.50 
3 34.03 12.52 17.71 6.13 41.67 7.16 67.71 12.22 66.67 9.08 82.50 9.35 
4 12.50 7.76 2.08 1.32 8.33 4.47 9.38 5.98 15.63 10.92 20.00 13.02 
5 2.08 1.42 1.04 1.04 4.17 2.64 9.38 4.19 2.08 2.08 15.00 7.29 
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Table 6 
Mean and SEM for area under the curve (AUC), indifference points (IPs), win:stay ratios 
(WSRs), and lose:shift ratios (LSRs) at each dose of CDP during chronic drug exposure. 
N = 6  
 Dose CDP (mg/kg) 
 Saline 1.0 3.0 10.0 17.0 30.0 
Measure M SEM M SEM M SEM M SEM M SEM M SEM 
AUC .22 .06 .13 .02 .24 .03 .30 .04 .31 .05 .31 .06 
IPs 2.37 0.82 1.53 0.22 2.54 0.47 3.78 0.60 3.96 .86 5.95 1.73 
WSRs .59 .01 .65 .02 .6. .04 .54 .04 .57 .03 .62 .06 
LSRs .91 .04 .76 .06 .85 .09 .84 .05 .87 .09 .87 .10 
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Figure 1 
Group means and SEM for percent larger-reinforcer choice as a function of probability of 
delivery during acute drug exposure. 





























Note. Percent larger-reinforcer choice in the third (25%) block was significantly higher for 1.0 (p 
= .01), 3.0 (p < .01), and 10.0 (p < .01) mg/kg CDP relative to saline. The acute 17.0 and 30.0 
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Figure 2 
Individual means and SEM for percent larger-reinforcer choice as a function of probability of 
delivery during acute drug exposure.  
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Figure 3 
Means and SEM for overall (full session) percent larger-reinforcer choice as a function of dose 





























Note. Overall percent larger-reinforcer choice was significantly higher relative to saline under 
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Figure 4 


























Note. Area under the curve was significantly higher relative to saline at 3.0 (p = .01) and 10.0 (p 
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Figure 5 
Mean and SEM for percent larger-reinforcer choice as a function of probability of delivery for 
acute saline, first five days of initial chronic drug exposure, and last five days of initial chronic 
drug exposure.  



























Note. Percent larger-reinforcer choice was significantly higher than saline during the first five 
days of chronic drug exposure (p = .04), but not the last five days.   
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Figure 6 
Mean and SEM for indifference points during the first and last five days of chronic drug 
exposure, as well as for baseline saline.  
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Figure 7 
Means and SEM for area under the curve during the first and last five days of chronic drug 
exposure, as well as for baseline saline. 
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Figure 8 
Means and SEM for win:stay ratios and lose:shift ratios during the first and last five days of 
chronic drug exposure, as well as for baseline saline. 
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Figure 9 
Group means and SEM for percent larger-reinforcer choice as a function of probability of 
delivery during chronic drug exposure. 






























Note. Percent larger-reinforcer choice was higher in the third (25%) block relative to saline at the 
10.0 (p < .01), 17.0 (p = .03), and 30.0 (p < .01) mg/kg doses of CDP.   
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Figure 10 
Means and SEM for percent larger-reinforcer choice as a function of probability of delivery for 
individual rats during chronic drug exposure.  
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Figure 11 
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Figure 12 

































CHLORDIAZEPOXIDE INCREASES RISKY CHOICE  71 
Figure 13 
Means and SEM for percent larger-reinforcer choice under saline during acute and chronic 
drug exposure.  
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Figure 14 
Means and SEM for overall (full session) percent larger-reinforcer choice as a function of dose 



































Note. The 17.0 and 30.0 mg/kg doses from the acute-exposure phase were excluded from 
analysis due to generalized response disruption. 
 
